Krsnaa Diagnostics Board Approves ₹430 Crore NCD Issuance
Krsnaa Diagnostics' Board approved the issuance of up to ₹430 crore in Unlisted, Secured, Redeemable Non-Convertible Debentures. The NCDs will have a 7-year tenure and will be redeemed in 13 equal installments starting 6 months post-allotment. The issuance is on a private placement basis.
The issuance of ₹430 crore in NCDs represents a significant amount of debt financing for the company, which could impact its capital structure and financial leverage. However, it is a planned fundraising activity and not an unexpected event.
The company is undertaking a debt fundraising activity which is a routine financial operation. The announcement does not contain any immediate positive or negative implications beyond the standard financial maneuver.
Krsnaa Diagnostics Limited announced today that its Board of Directors, in a meeting held on December 12, 2025, has approved the issuance of Unlisted, Secured, Redeemable, and Transferable Non-Convertible Debentures (NCDs) for an amount up to ₹430 crore.
The issuance will be conducted on a private placement basis. The company plans to issue 43,000 NCDs, each with a face value of ₹1,00,000, aggregating to a total of ₹430 crore. These NCDs will have a tenure of seven years from the deemed date of allotment.
The coupon/interest offered is at a fixed rate. The interest and principal will be payable on a half-yearly basis, with the company scheduled to redeem the debentures in thirteen equal installments commencing six months from the allotment date. A charge will be created over identified assets of the Company as security for the issuance.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.